Romidepsin for the treatment of relapsed or refractory peripheral T-cell lymphoma
Please note that following on from information provided to NICE by the company in July 2012, the appraisal of Romidepsin for the treatment of relapsed or refractory peripheral T-cell lymphoma [ID504] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 504
Referral date 01 November 2011
Topic area
  • Cancer

Provisional Schedule

Closing date for invited submissions / evidence submission: 22 June 2012
1st appraisal committee meeting: TBC

Project Team

Communications manager: Laura Gibson
Executive Lead: TBC
Project manager: Rebecca Pye
Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
23 January 2023 Discontinued. Please note that following on from information provided to NICE by the company in July 2012, the appraisal of Romidepsin for the treatment of relapsed or refractory peripheral T-cell lymphoma [ID504] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
23 November 2012

Following an update on the regulatory status of this technology which has received a negative CHMP opinion, this appraisal remains suspended whilst we consider the next steps.

10 July 2012

The manufacturer of romidepsin has informed NICE that they will not provide an evidence submission for this appraisal. NICE has therefore suspended this appraisal.

22 February 2012

Following on from advice received from the manufacturer, this appraisal has now been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late April 2012 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late June 2012.


For further information on our processes and methods, please see our CHTE processes and methods manual